Indication
esophageal squamous cell carcinoma
1 clinical trial
3 products
Clinical trial
A 3-Arm, Randomized, Blinded, Active-Controlled, Phase II Study of RO7121661, a PD1-TIM3 Bispecific Antibody and RO7247669, a PD1-LAG3 Bispecific Antibody, Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the EsophagusStatus: Active (not recruiting), Estimated PCD: 2025-06-30
Product
LomvastomigProduct
TobemstomigProduct
Nivolumab